Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment Celltrion proudly announces the FDA's approval of EYDENZELT®, a biosimilar to EYLEA®, enhancing treatment options for retinal diseases like AMD and DME.

Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment #South_Korea #FDA_Approval #Incheon #Celltrion #EYDENZELT